VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply

Viking Therapeutics (VKTX) signed a broad multi-year manufacturing agreement with CordenPharma, a contract development and manufacturing organization (CDMO), for both the oral and subcutaneous (SC) formulations of its obesity drug VK2735.Per the terms, Viking has secured dedicated manufacturing capacity to support the large-scale production of VK2735. The deal includes an annual supply commitment for multiple metric tons of the active pharmaceutical ingredient (API) behind VK2735, along with fill/finish cap ...